A Study of the Cardiac Effects of ALXN2050 in Healthy Adults
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel
study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharmaceuticals
Collaborator:
Celerion
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination